Other Events ·
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) received European Union approval as a monotherapy…
AZNAstrazeneca PLC
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) received European Union approval as a monotherapy for adult patients with unresectable or metastatic HER2-positive solid tumours who have received prior treatment. The approval is based on results from three Phase II trials: DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02. As a result of this approval, AstraZeneca will make a $25 million milestone payment to Daiichi Sankyo. AstraZeneca is a global biopharmaceutical company that develops and commercialises prescription medicines in oncology, rare disease, and biopharmaceuticals.